With Constant Efforts by the Governments to Reduce the Emission Levels Across the Globe, the Global Industrial Absorbents Market Shall Witness a Consistent Growth From 2019 to 2027, Noted TMR
Threat of chemical weapons is constantly lurking over various countries across the globe. A notable event of drones attack on the oil facility of Saudi Arabia, at Abqaiq has raised alarms amongst various governments about the impact chemical weapons. The effective counter measure for such affects is the implementation absorbents around oil and gas refineries. Owing to these demands, the global industrial absorbents market is expected to grow substantially in the forecast period of 2019 to 2027, says a recent report by Transparency Market Research. As per the report, the global industrial absorbents market is projected to experience 4% CAGR during the tenure. Moreover, the market is also anticipated to reach to the value of ~US$ 5.4 Bn by the end of 2027.
Download PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55773
Major Findings in the Global Industrial Absorbents Market Study
- Oil and gas segment under end-user industry is projected to provide exceptional opportunities to the player of the global industrial absorbents market. Owing to these opportunities the segment shall emerge as the largest segment in the global industrial absorbents market.
- In 2018, the synthetic absorbents under material type dominated the global industrial absorbents market. The segment is projected to continue its dominance in the coming years between 2019 and 2027. This dominance of the segment was attributed to the factors such as ease of production and cost-effectiveness. As per the report, the segment shall account for more than 76% of overall share of the global industrial absorbents market.
Explore the latest study on industrial absorbents market under the title: Industrial Absorbents Market (Material: Synthetic and Natural; Product: Oil-only, Universal, and HAZMAT/Chemical; and End-use Industry: Chemicals, Oil & Gas, Food Processing, and Others [Healthcare, Aerospace, Life Sciences, Mechanical Workshops, and Garages]) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027 at https://www.transparencymarketresearch.com/industrial-absorbents-market.html
Major Drivers of Global Industrial Absorbents Market Mentioned in the Study
Demand to Reduce Environmental Pollutants
Due to growing industrializations, the pollution levels across the globe have spiked significantly in recent years. This rise in the level has created alarming situations in countries like U.S. and China. India being a developing economy is extensively welcoming new industries. However, these industries are increasing the risk of elevated pollution with the growing number of industries coupled with vehicles on the road. Due to these alarming situations, the demand for effective industrial absorbents has skyrocketed in recent years. Owing to these demands, the global industrial absorbents market shall experience massive momentum in coming years between 2019 and 2027.
Stringent Government Policies to Propel the Growth
Since, the pollution level are exceeding beyond controllable limits, the governments have made it mandatory for the industries to implement effective absorbents in their facilities. This is also a crucial factor that is propelling the growth of global industrial absorbents market during the tenure of 2019 to 2027. Additionally, several non-governmental organizations are constantly stimulating the demand for industrial absorbents around factories and refineries. This shall also propel the growth of global industrial absorbents market during the estimated time frame, says the report by Transparency Market Research.
View Detailed Table of Contents at https://www.transparencymarketresearch.com/report-toc/55773
Global Industrial Absorbents Market: Regional Analysis
In terms of value and volume, North America constituted a major share of the global industrial absorbents market in 2018, and the trend is projected to continue during the forecast period. The presence of key manufacturers of industrial absorbents and availability of raw materials are expected to boost the market in North America in the next few years. The U.S. led the industrial absorbents market in North America, holding more than 66% of the market share in 2018. The market share of the country is expected to increase by 1% by 2027.
The global industrial absorbents market is highly competitive and moderately fragmented. This nature of the market is the result of the presence of a handful of prominent players that are dominating the dynamics of the market. However, due to this scenario, the new players might find it difficult to enter the global industrial absorbents market.
Therefore, these players are indulging in strategies such as mergers and collaborations to acquire adequate resources that can help them gain sustainability in the global industrial absorbents market.
Analyze Industrial Absorbents Market growth in 30+ countries including US, Canada, Germany, United Kingdom, France, Italy, Russia, Poland, Benelux, Nordic, China, Japan, India, and South Korea. Request a sample of the study
The global industrial absorbents market is segmented on the basis of:
Industrial Absorbents Market by Material
Industrial Absorbents Market by Product
Industrial Absorbents Market by Product
- Oil & Gas
- Food Processing
Industrial Absorbents Market by Region
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific (APAC)
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Explore Transparency Market Research’s award-winning coverage of the global Chemicals and Materials Industry,
U.S. Graphite Electrodes Market – The graphite electrodes market in the U.S. was valued at US$ 939.11 Mn in 2018 and is anticipated to expand at a CAGR of ~2% from 2019 to 2027. Increase in demand for graphite electrodes in various end-use industries in the U.S. is driving the graphite electrodes market in the country.
Ink Resins Market – The global ink resins market was valued at US$ 3.0 Bn in 2018 and is anticipated to expand at a CAGR of more than 5.0% from 2019 to 2027, according to a new research report published by Transparency Market Research
Plastics Market for Electrical Appliances – Global production of plastic stood at 322 million tons in 2015 and is estimated to increase at a CAGR of 6% to 7% by 2020. On the basis of region, Asia Pacific was the fastest growing regional and was 2/3rd of the total revenue in 2017. The revenue share of the region was more than 50%.
Metalworking Fluids Market – In terms of value, the global Metalworking Fluids market was stood around US$ 11.0 Bn in 2018 and is anticipated to expand at a CAGR of more than 4% from 2019 to 2027
Carbonyl Nickel Powder Market – Some of the top factors that are expected to influence the carbonyl nickel powder market growth include an emphasis on the production of electric vehicles, industrialization in Asia Pacific, and soaring demand for carbonyl nickel powder from the chemical industry.
Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor’s moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage’s actionable insights and remove the guesswork in making colossal decisions.
Aidéo Technologies Launches Free Use of AI-Powered Automated CPT and Diagnosis Coding During the US Response to COVID-19
MELBOURNE, Fla., April 01, 2020 (GLOBE NEWSWIRE) — Aidéo Technologies – a leader in AI-enabled automation technology for the healthcare industry – announced today that it will allow healthcare organizations and revenue cycle management companies to utilize its AI enabled medical coding engine Gemini AutoCode™ free of charge in response to COVID-19.
COVID-19 has disrupted the global revenue cycle management workforce and created challenges for organizations lacking a secure infrastructure to allow employees to work from home while under shelter-in-place mandates. As a by-product, physician practice and hospital revenue are negatively impacted.There is a growing concern over security of US patient data as many companies cannot meet security requirements in a work from home environment. “Aidéo Technologies wants to help the US Healthcare Delivery System remain financially viable during this national crisis,” said Rob Gontarek, the President and CEO of Aidéo Technologies. “We are making our technology platform available at no cost for the duration of the crisis to affected providers and revenue cycle management companies. Organizations can gain immediate access to a secure solution to the disruption in the global workforce.” The business continuity of medical groups and hospitals can be maintained using the machine learning models for medical coding through Gemini AutoCode™.Gemini AutoCode™ uses AI, a proprietary Natural Language Processing engine, and machine learning to interpret structured and unstructured clinical data. The application assigns the appropriate procedure and diagnosis codes, with no human intervention required. Gemini AutoCode™ easily integrates with electronic medical records and can accurately interpret and code over forty-thousand clinical encounters per hour.It is expected that COVID-19 will have a lasting impact on the US Healthcare Delivery System and the machine learning of Gemini AutoCode™ will offer relief to entities impacted by the crisis. For more information, please visit www.aideo-tech.com/howcanwehelp?About Aidéo Technologies
Aidéo Technologies (www.aideo-tech.com) provides software automation tools using artificial intelligence, robotics, and machine learning to the healthcare industry. Established in 2009, the company has development centers in Melbourne, Florida, and Silicon Valley. Aidéo is a portfolio company of Avtar Investments (www.avtarinvestments.com), a private family office investment firm focused on disruptive technology in healthcare.Contact:
Senior Director, Client Service
2nd Gen AMD EPYC™ Processors Power New IBM Cloud Bare Metal Servers
SANTA CLARA, Calif., April 01, 2020 (GLOBE NEWSWIRE) — Today, AMD announced that IBM Cloud is enhancing its global infrastructure with 2nd Gen AMD EPYC™ processors to power its latest bare metal servers. With the addition of the AMD EPYC 7642 processor to its cloud portfolio, IBM is engineered to deliver increased computing performance in its bare metal offerings. Available now, these new bare metal servers are the first 2nd Gen AMD EPYC™ based offering from IBM Cloud and are focused on the computing power and performance required to accelerate modern workloads like data analytics, electronic design automation, artificial intelligence and virtualized and containerized workloads.
“2nd Gen AMD EPYC processors deliver where it counts for cloud providers, providing the cores, scalability and throughput for critical workloads,” said Forrest Norrod, senior vice president and general manager, Data Center and Embedded Solutions, AMD. “We are extremely excited to extend the advantages of 2nd Gen AMD EPYC processors to new bare metal offerings at IBM Cloud, helping customers tackle today’s compute-intensive workloads.”“We are thrilled to launch new IBM Cloud offerings powered by the 2nd Gen AMD EPYC CPUs,” says Satinder Sethi, GM, IBM Cloud Infrastructure Services. “With these new processors, we can offer IBM Cloud clients greater choice and flexibility to select the platform that is best suited to meet the needs of today’s most demanding workloads. We look forward to continuing to deliver new innovations and value to our clients in the future.”The AMD EPYC 7642 based, dual socket bare metal server offering at IBM Cloud includes:96 CPU cores per platformBase clock frequency of 2.3GHz with a Max Boost up to 3.3GHzi8 memory channels per socket for superior memory bandwidthUp to 4TB memory configuration supportUp to 24 local storage drivesOS choices of RHEL, CentOS, Ubuntu, MS ServerMonthly, pay-as-you-use billingOrderable via the global IBM Cloud Catalogue, API, or CLIThe bare metal servers are being made available in IBM Data Centers across the North America, Europe, and Asia Pacific regions. The AMD EPYC 7642 based servers can be ordered via the IBM Cloud global catalogue portal, API or CLI and consumed in a monthly pay-as-you-use model. Visit IBM Cloud to start building a bare metal server configuration with 2nd Gen AMD EPYC processors.Supporting ResourcesLearn more about IBM Cloud Bare Metal ServersRead more at the IBM BlogLearn more about the AMD 2nd Gen EPYCTM ProcessorBecome a fan of AMD on FacebookFollow AMD on TwitterAbout AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies ― the building blocks for gaming, immersive platforms and the datacenter. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world rely on AMD technology daily to improve how they live, work and play. AMD employees around the world are focused on building great products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, Facebook and Twitter pages.AMD, the AMD Arrow logo, EPYC, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.i Max boost for AMD EPYC processors is the maximum frequency achievable by any single core on the processor under normal operating conditions for server systems. EPYC-18
(512) 602-8950 Laura Graves
AMD Investor Relations
Predictive Oncology Reports 2019 Full-year Financial Results
MINNEAPOLIS, April 01, 2020 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its full year ended December 31, 2019, as well as select corporate highlights.Q4 HighlightsSecured $15.0 Million equity line with Oasis Capital, LLCNew subsidiary Helomics reached milestone sequencing tumor cases in partnership with UPMC MageeSubsidiary Skyline Medical completed largest STREAMWAY™ System order to a single hospital in the Company’s historyLaunched CancerQuest 2020 initiative, with ovarian cancer initial targetFull-Year 2019 Results – 2019 vs. 2018Revenues were $1.4 million, flat year on year relative to $1.4 million in 2018Net loss was $19.7 million versus $10.1 million in 2018, owing in part to Helomics merger expenses, goodwill impairment, and other extraneous expenses related to the transaction.Bob Myers, CFO of Predictive Oncology, stated, “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up our balance sheet via a new $15.0 million equity line from Oasis Capital. Our STREAMWAY line has maintained strong disposable product sales and we continue to sell the STREAMWAY System.”“We continue to be very excited about the revenue and monetization prospects for our precision medicine business, which will allow us to be at the forefront of developing the artificial intelligence required to combat a variety of ailments, as well as our revolutionary STREAMWAY clinical waste disposal products,” stated Dr. Carl Schwartz, CEO and Director. “We will continue to execute upon our comprehensive strategy to deliver long-term profitable growth and innovation while concentrating our efforts and resources on our recently acquired Helomics business.”“Building on the successes in 2019, we have recently announced the launch of our CancerQuest 2020 initiative, and we expect Helomics’ first AI-driven predictive model of ovarian cancer to be ready for initial commercialization in revenue generating projects with Pharma in Q2-2020,” Dr. Schwartz added. “Furthermore, we have signed a Letter of Intent to acquire Quantitative Medicine, a biomedical analytics and computational biology company. Against this backdrop, we believe that Predictive Oncology will continue to be a pioneer within the fields of biomarker discovery and precision therapies going forward.”FULL-YEAR 2019 RESULTSRevenues were $1.4 million, consistent with 2018. Revenues in both years were primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY units, of which 43 units and 41 units were sold, respectively, in each of 2019 and 2018. Gross margins remained strong, declining slightly to 62% in 2019, from 71% in 2018, largely due to the increase in costs following the consolidation of the Helomics acquisition on April 4, 2019. However, exclusive of Helomics, the cost of sales related to the sale of STREAMWAY products was comparable on a year-on-year basis.Net losses for 2019 totaled $19.7 million versus $10.1 million in 2018. General & administrative expenses rose 111% to nearly $9.8 million in 2019 as a result of extraneous expenses and initial costs related to the Helomics merger. In addition, Predictive Oncology recognized a credit loss of $1.0 million in notes receivable from CytoBioscience (now operating as InventaBioTech). Operational expenses also rose to $3.0 million, compared to $1.8 million in 2018. Net loss in 2019 reflected impairment charges of $8.1 million on goodwill related to the Helomics merger and $0.8 million on intangibles, versus no impairment charges in 2018.Separately, the Company benefited from a gain of $6.1 million as a result of the revaluation of the equity method investment recorded post the initial 25% purchase of Helomics, following the merger and consolidation of Helomics effective April 4, 2019. Predictive Oncology also incurred other expenses of $4.0 million in 2019 compared to only $441,000 in 2018, primarily due to an increase in interest expense, payment penalties, amortization of original issue discounts and a loss on debt extinguishment related to our notes payable.OUTLOOKGoing forward, management intends to focus its resources on the Helomics and TumorGenesis divisions and the Company’s primary mission of applying artificial intelligence to precision medicine, drug discovery and the mediums used to replace rats and mice in preliminary cancer studies. Predictive Oncology had previously reported in December 2019 that it had received several indications of interest for the possible acquisition of its Skyline Medical division (which owns and markets the Company’s proprietary STREAMWAY System) no further action has resulted from these indications, and today management reaffirms that it is focusing the majority of its resources on maximizing opportunities within the Company’s precision medicine business.About Predictive Oncology Inc.Predictive Oncology (Nasdaq: POAI) operates through three segments (Domestic, International and Helomics), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.predictive-oncology.com.Forward-looking StatementsPortions of the narrative set for this this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein:
We may not be able to continue operating without additional financing;Current negative operating cash flows;The terms of any further financing, which may be highly dilutive and may include onerous terms;Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;Risks related to the transaction with Quantitative Medicine including: 1) completion of the transaction; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;Risk that we will be unable to complete the transaction with InventaBio Tech;Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;The impact of competition;Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;Risk that we never become profitable if our product is not accepted by potential customers;Possible impact of government regulation and scrutiny;Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;Adverse results of any legal proceedings;The volatility of our operating results and financial condition, and,Other specific risks that may be alluded to in this report.Contact:
Predictive Oncology, Inc.
Consolidated Balance Sheets
Predictive Oncology, Inc.
Consolidated Statements of Operations
Latest News9 months ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence11 months ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence12 months ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence10 months ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence12 months ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence12 months ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence10 months ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence6 months ago
Mogo announces a digital lending pilot with goeasy Ltd.